Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC
Written by
Cancer Network
Published
0
comments
0
min
Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.